JPMorgan analyst Eric Joseph lowered the firm’s price target on Rocket Pharmaceuticals (RCKT) to $44 from $45 and keeps an Overweight rating on the shares following the Q1 report. The firm continues to see Rocket shares underappreciating the potential value from the company’s gene therapy portfolio and especially the cardiomyopathy franchise.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RCKT:
- Promising Outlook for Rocket Pharmaceuticals: Strategic Leadership, Robust Financials, and Advancements in Danon Disease Program Drive Buy Rating
- Rocket Pharmaceuticals Reports Q1 2025 Financial Results
- Promising Outlook for Rocket Pharmaceuticals: Buy Rating Affirmed Amidst Strong Pipeline and Financial Stability
- Optimistic Buy Rating for Rocket Pharmaceuticals Driven by Promising Gene Therapy Developments and Market Potential
- Rocket Pharmaceuticals reports Q1 EPS (56c), consensus (58c)